Question 1

What is Alyssa Johnsen?

Accepted Answer

Alyssa Johnsen is a Person.

Question 2

How often does Alyssa Johnsen appear in global news?

Accepted Answer

Tracked across 2 news events drawn from 16 articles.

Question 3

When was Alyssa Johnsen first tracked by Ergen?

Accepted Answer

First tracked on Feb 24, 2026.

Question 4

When was Alyssa Johnsen last mentioned in news?

Accepted Answer

Last active on May 27, 2026.

Question 5

What is Alyssa Johnsen's current news sentiment?

Accepted Answer

Aggregate sentiment score: 0 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Alyssa Johnsen in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 2 events.

Question 7

What is the most recent event involving Alyssa Johnsen?

Accepted Answer

Dupixent Approved for Pediatric CSU in EU (Apr 13, 2026, 8 articles).

Question 8

How did the "Dupixent Approved for Pediatric CSU in EU" event impact Alyssa Johnsen?

Accepted Answer

Alyssa Johnsen, Global Therapeutic Area Head, Immunology Development at Sanofi, emphasized Dupixent's innovative approach to treating chronic spontaneous urticaria in young children.

Question 9

How did the "Dupixent EU Recommendation, US Approval" event impact Alyssa Johnsen?

Accepted Answer

Alyssa Johnsen, Global Therapeutic Area Head, Immunology Development at Sanofi, highlighted the benefits of Dupixent's approval for allergic fungal rhinosinusitis (AFRS).

Question 10

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.